Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/II trial tests the safety, side effects, and best dose of entinostat and ZEN003694 in treating patients with solid tumors that have spread to other places in the body (advanced) or does not respond to treatment (refractory). Entinostat is in a class of drugs called histone deacetylase (HDAC) inhibitors. It may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. This trial aims to test the safety of combination therapy with entinostat and ZEN003694 in treating patients with advanced or refractory solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie zaawansowanego lub opornego na leczenie nowotworu litego, spełniającego standardowe wymagania do leczenia
- •Na etapie II badania: zaawansowany rak trzustki oporny na standardowe leczenie
- •Możliwość zmierzenia zmian w guzie według standardowych kryteriów oceny
- •Poprzednie leczenie standardowe z powodu zaawansowanego nowotworu
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na leczenie (wynik ECOG 0-1)
- •Wyniki badań krwi w normie: hemoglobina ≥9,0, neutrocyty ≥1500, płytki ≥100 000
- •Wyniki testów wątroby i nerek w normie (badania wykonane do 14 dni przed rozpoczęciem leczenia)
✗ Disqualifies
- •Wiek poniżej 18 lat
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Yale University
New Haven, United States
UF Health Cancer Institute - Gainesville
Gainesville, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
Trial contact
Site Public Contact
Patricia M. LoRusso
PRINCIPAL_INVESTIGATOR
Site Public Contact
Thomas J. George
PRINCIPAL_INVESTIGATOR
Site Public Contact
Abdul Rafeh Naqash
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.